FY2026 Q3 Financial Summary [Japanese GAAP] (Consolidated)

Overview of Business Results

Consolidated net sales for FY2026 Q3 reached 101.016 billion yen, a 4.7% increase YoY, marking the highest level since quarterly disclosure began. Operating income declined 2.4% YoY to 11.035 billion yen due to higher personnel and other expenses. Ordinary income slightly decreased by 0.1% YoY to 14.184 billion yen, driven by gains on foreign exchange and others. Net income attributable to owners of the parent for the quarter was 9.374 billion yen, down 1.9% YoY, reflecting gains on sales of investment securities and other factors. By segment, the Pharmaceuticals segment recorded net sales of 43.988 billion yen (1.7% YoY increase) and operating income of 7.153 billion yen (10.2% YoY decrease); the Equipment segment posted net sales of 18.556 billion yen (18.8% YoY increase) and operating income of 1.247 billion yen (214.1% YoY increase); and the Processing segment reported net sales of 36.165 billion yen (1.8% YoY increase) and operating income of 3.680 billion yen (0.6% YoY decrease).

Financial Position and Outlook

Total assets stood at 259.113 billion yen, down 8.136 billion yen from the previous fiscal year-end, while net assets decreased by 8.912 billion yen to 214.386 billion yen, mainly due to an increase in treasury stock. The equity ratio rose 1.9 points to 74.9%. There is no revision to the consolidated earnings guidance for FY2026, with projected net sales of 131.0 billion yen (1.0% YoY decrease), operating income of 14.0 billion yen (6.7% YoY decrease), and net income attributable to owners of the parent of 12.0 billion yen (8.5% YoY decrease). The dividend forecast remains unchanged at 50.00 yen per share.